Guardant Health, Inc. (NASDAQ:GH) Receives $141.95 Average Target Price from Brokerages

Guardant Health, Inc. (NASDAQ:GH) has been assigned an average recommendation of “Moderate Buy” from the twenty-three analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, twenty-one have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $142.1905.

Several brokerages recently issued reports on GH. UBS Group set a $150.00 target price on Guardant Health in a research note on Wednesday. Wolfe Research began coverage on Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. The Goldman Sachs Group began coverage on Guardant Health in a research note on Friday, June 5th. They set a “buy” rating and a $165.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Finally, Barclays lifted their target price on Guardant Health from $120.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday.

Insider Activity at Guardant Health

In other Guardant Health news, Director Steve E. Krognes sold 9,294 shares of Guardant Health stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $132.51, for a total value of $1,231,547.94. Following the sale, the director owned 10,222 shares of the company’s stock, valued at $1,354,517.22. The trade was a 47.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. The trade was a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 452,513 shares of company stock worth $51,608,916 in the last three months. Corporate insiders own 5.60% of the company’s stock.

Institutional Trading of Guardant Health

Large investors have recently added to or reduced their stakes in the company. Erste Asset Management GmbH boosted its holdings in Guardant Health by 10.4% during the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after acquiring an additional 66,617 shares during the period. World Investment Advisors purchased a new position in Guardant Health during the 4th quarter valued at $1,664,000. Segall Bryant & Hamill LLC boosted its holdings in Guardant Health by 57.8% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after acquiring an additional 111,822 shares during the period. TD Asset Management Inc boosted its holdings in Guardant Health by 16.1% during the 3rd quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock valued at $11,797,000 after acquiring an additional 26,210 shares during the period. Finally, GSA Capital Partners LLP lifted its holdings in shares of Guardant Health by 155.5% in the 3rd quarter. GSA Capital Partners LLP now owns 21,982 shares of the company’s stock worth $1,373,000 after buying an additional 13,378 shares during the period. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Up 4.4%

Shares of GH opened at $142.94 on Friday. The business’s 50 day moving average is $111.34 and its 200 day moving average is $103.70. The company has a market capitalization of $18.95 billion, a PE ratio of -42.17 and a beta of 1.61. Guardant Health has a 12-month low of $40.35 and a 12-month high of $145.84.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.